Philips CPAP Cancer Lawsuit News

Former Phillips CPAP Users May Not Get A Replacement For Months

The FDA has gone on record as saying that the malfunctions of the Phillips CPAP machines are life-threatening

Wednesday, August 18, 2021 - It is often the case that a consumer product recall leaves the former users confused, scared, and in need of answers. When the Food and Drug Administration (FDA) recalled Zantac heartburn and acid reflux medicine, millions of Americans woke up that day unable to purchase their favorite brand of antacid. When Johnson & Johnson decided to stop selling their iconic brand of talcum powder in the United States over fears that it also contains asbestos, a known and deadly carcinogen, consumers were scared that they may have developed cancer. While it was relatively simple to purchase another brand of heartburn medicine or pick up a different brand of baby powder, people with sleep apnea face a more pressing situation. In the wake of the Phillips CPAP recall users may have to wait more than a year before a replacement is available.

People with sleep apnea must wear a head set-like device to sleep that forces air into the airway through the nose and prevents snoring or gasping for air. Without the device, sleep apnea patients wake up multiple times per night, often from their snoring. According to the New York Times, "In June of 2021, more than a dozen Philips Respironics machines that deliver pressurized air through a mask were recalled because of potential health risks from faulty components. Since then, millions of people in the United States, and their doctors, have been scrambling to find alternatives for those with common sleep disorders, breathing problems, and respiratory emergencies.

Sleep apnea patients that have used one or more of the devices and have developed lung problems, respiratory complications, and in some cases lung cancer, have spoken with an attorney and filed a CPAP Cancer Lawsuit for lump sum monetary compensation and punitive damages. The Times reports that The Food and Drug Administration warned that the Phillips CPAP malfunctions could cause permanent lung damage and cancer because some of the components of the machine that are intended to dampen down the noise it makes and make it quieter to run degrades, throw off toxic, poisonous gases and particle that go directly into the tubes that the patient attaches to the nose and airways. "Last month, the Food and Drug Administration warned of potential health risks that could be “life-threatening, cause permanent impairment and require medical intervention.” The potential harm comes from polyester-based polyurethane foam that dampens sound and vibration in the machines; it can degrade and result in a user’s breathing in chemicals or swallowing or inhaling black debris," warned the NYT. The FDA told the public that the particles and gassed the defective machine produces could cause "asthma, skin and respiratory tract irritation and toxic and carcinogenic effects to organs including the kidneys and liver. The Phillips CPAP recalls are causing shortages in hospitals and emergency rooms that rely on ventilators to treat Covid-19 patients.

">

More Recent Philips CPAP Cancer Lawsuit News:

Lawyers for CPAP Cancer Lawsuits

We will represent all persons in involved in a BiPAP or CPAP cancer lawsuit on a contingency basis, meaning there are never any legal fees unless we win compensation in your case. Anyone who developed cancer or another serious side effect as a result of using a Philips CPAP sleep apnea machine or ventilator in --or is a family member of such a person--is eligible to receive a free, no-obligation case review from our attorneys. Simply contact our firm through the online contact form or the chat feature and one of our Philips BiPAP cancer lawyers serving will contact you promptly to discuss your case.



Privacy Notice: This site uses cookies for advertising, analytics and to improve our site services. By continuing to use our site, you agree to our use of cookies. For more information, see our cookie and privacy policy.